Navrogen
Latest round
- Seed
Last raised
- Aug 2021
Total raised
- $3M
Investors
- 1
About Navrogen
Navrogen, Inc.Founded in 2017 in the United States, Navrogen, Inc. specializes in creating innovative solutions for addressing cancer-related immune suppression. The company’s leadership includes CEO Nicholas Nicolaides, who guides the firm’s strategic direction.Navrogen specializes in the development of innovative therapeutic agents and diagnostic tools aimed at overcoming immunosuppressive mechanisms in the field of Humoral Immuno-Oncology. Their core product offerings include the antibody-drug conjugate (ADC) NAV-001, which targets mesothelin and employs a novel payload that is resistant to CA125 inhibition, and NAV-006, a next-generation rituximab designed to enhance effector functions against immunosuppressed follicular lymphoma. These products are targeted towards oncologists and healthcare professionals who treat cancer patients, with the intention of improving therapeutic options for individuals impacted by tumors that suppress humoral immune responses.Navrogen's revenue generation model is based on collaborations with healthcare institutions, pharmaceutical companies, and research organizations. The company engages in direct partnerships for the development and commercialization of its proprietary therapeutic agents, such as NAV-001 and NAV-006, which are integral to their offerings. The financial transactions typically involve milestone payments associated with clinical trial advancements and potential royalties on product sales upon market approval. Pricing structures are established through negotiations with institutional buyers and partners that recognize the value of innovative therapies in the oncology space.In August 2021, Navrogen, Inc. The company plans to utilize these funds to advance its lead HIO-refractory, anti-mesothelin NAV-001 antibody-drug conjugate program and its NK cell activator platforms that specifically address HIO suppressed cancers and immune-mediated diseases. Navrogen is focused on developing new products while expanding its presence in international markets where advanced immunotherapy treatments are needed.
Who invested in Navrogen
1 investor across 1 round
See all investors in Navrogen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Aug 9, 2021
Amount
$3M
Investors
Questions about Navrogen
Who invested in Navrogen?
Navrogen has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Navrogen raised?
Navrogen has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Navrogen last raise money?
Navrogen's most recent round on record is a Seed, in Aug 2021.
What does Navrogen do?
Navrogen is a biotechnology company.
Where is Navrogen headquartered?
Navrogen is headquartered in US.
Which VCs invest in companies like Navrogen?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Navrogen's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Navrogen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.